Jie Xu, MD

Consultant
Peking University People's Hospital, China (People's Republic)

I am Jie Xu, consultant of Musculoskeletal Tumor Center of Peking University People’s Hospital, Beijing, China. I am a specialist in soft tissue and bone sarcomas and work as a pediatric and medical oncologist, interested in the systemic treatment of Ewing sarcoma, osteosarcoma, rhabdomyosarcoma and chondrosarcoma, including chemotherapy, targeted therapy and immunotherapy.

Poster(s):

• (P 51) OAIE TRIAL IN PROGRESS: A RANDOMIZED PHASE II TRIAL ASSESSING APATINIB IN COMBINATION WITH IFOSFAMIDE AND ETOPOSIDE(IE) VERSUS SINGLE IE CHEMOTHERAPY FOR RELAPSED OR REFRACTORY OSTEOSARCOMA

• (P 52) ARTEMIS-002 TRIAL IN PROGRESS: A MULTI-CENTER PHASE II TRIAL ASSESSING HS-20093 (B7-H3 ANTIBODY-DRUG CONJUGATE) FOR RELAPSED OR REFRACTORY OSTEOSARCOMA AND OTHER SARCOMAS

• (P 97) AN EXPLORATORY STUDY OF AN ANTI-PD-L1/TGF-β ANTIBODY, TQB2858, IN PATIENTS WITH REFRACTORY OR RECURRENT OSTEOSARCOMA AND ALVEOLAR SOFT PART SARCOMA: A REPORT FROM CHINESE SARCOMA STUDY GROUP

• (P 441) LONG VERSUS SHORTER SCHEDULES OF VINCRISTINE, IRINOTECAN AND TEMOZOLOMIDE (VIT) FOR RELAPSED OR REFRACTORY EWING SRACOMA: A RANDOMISED CONTROLLED PHASE 2 TRIAL

• (P 442) LONG-TERM OUTCOME AND RELAPSE PATTERNS IN EWING SARCOMA PATIENTS WITH EXTENSIVE LUNG/PLEURAL METASTASES AFTER A COMPLETE RESPONSE TO SYSYEMIC THERAPY